Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


US Insulin Pricing Probe Clouds Prospects for Novo Nordisk, Others

Executive Summary

As US prosecutors investigate Novo Nordisk and other insulin makers for their pricing and contracts with pharmacy benefit managers, plaintiff firms allege the Danish group engaged in collusive agreements and misled investors about its earnings and forecasts.


Related Content

Lilly Shows Diabetes Dominance, But Will It Last?
Spring Break: Novo's US Head Resigns After Rough Winter
Janssen's Drug Pricing Report Emphasizes Value Of Rebates
Generic Industry Hit With Avalanche Of Price Fixing Suits
Diabetes Rebate Model Challenged On Morality Grounds In Class Action Suit
Lilly’s Insulin Discounts Target High-Deductible Insurance Gaps
Winter Is Coming: What Can Novo Nordisk Do Next After Stock Fall?
Pharma Deals With The DOJ
Pharma Pricing, Non-Profit Ties Get Increasing Scrutiny From Prosecutors


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts